Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing gastric acid secretion (basal and stimulated) by inhibiting c AMP production.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of active duodenal ulcer,Maintenance therapy for duodenal ulcer,Treatment of active benign gastric ulcer,Treatment of erosive gastroesophageal reflux disease (GERD),Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Prevention of upper gastrointestinal bleeding in critically ill patients (off-label),Prophylaxis of aspiration pneumonitis during anesthesia (off-label)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
300 mg intravenously every 6-8 hours or as continuous IV infusion at 37.5-50 mg/hour. Maximum 2400 mg/day.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
2-3 hours in normal renal function, prolonged to >8 hours in severe renal impairment (Cr Cl <20 m L/min).
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Metabolized primarily in the liver via CYP450 enzymes, including CYP1A2, CYP2C19, CYP2D6, and CYP3A4; undergoes sulfoxidation and N-demethylation.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal (75% as unchanged drug via glomerular filtration and tubular secretion); hepatic metabolism (25%); fecal (<10%).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
13-25% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
1-2 L/kg, indicating extensive distribution into tissues, including liver, kidney, and gastric mucosa.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: 60-70% (first-pass metabolism); IM: 100% bioequivalent to IV.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Cr Cl 10-50 m L/min: 300 mg every 12 hours. Cr Cl <10 m L/min: 300 mg every 24 hours.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment recommended. In severe hepatic impairment, reduce dose or prolong interval due to increased half-life; use with caution.
No dosage adjustment required for hepatic impairment.
Neonates: 5-10 mg/kg/day IV divided every 8-12 hours. Children: 20-40 mg/kg/day IV divided every 6 hours, max 800 mg/day.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Reduce dose or prolong interval due to age-related renal impairment; consider creatinine clearance and adjust accordingly.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
No FDA boxed warning for cimetidine hydrochloride.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
May cause confusion and delirium, especially in elderly or renally impaired patients; dose adjustment required for renal impairment.,Potential for drug interactions due to inhibition of CYP450 enzymes; monitor for interactions with warfarin, theophylline, phenytoin, lidocaine, and others.,Avoid rapid intravenous administration to prevent cardiac arrhythmias (bradycardia, hypotension).,Reversible gynecomastia and impotence may occur with prolonged use.,Neutropenia and thrombocytopenia reported rarely.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Known hypersensitivity to cimetidine or any component of the formulation.,Use with caution in patients with renal impairment (dose adjustment required); contraindicated in patients with severe renal impairment if unable to adjust dose.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid alcohol, caffeine, and spicy foods as they may exacerbate gastric irritation. Cimetidine can increase caffeine levels; limit caffeine intake. No significant food-drug interactions, but a high-protein meal may delay absorption when given orally, though IV route bypasses this.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Cimetidine crosses the placenta. First trimester: No increased risk of major malformations in human studies, but animal studies show fetal effects at high doses. Second and third trimesters: Risk of transient neonatal hepatic dysfunction and possible androgen anti-androgen effects; use only if clearly needed.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Cimetidine is excreted into breast milk; milk-to-plasma ratio approximately 0.5-1.0. Due to potential for adverse effects (e.g., CNS stimulation, gastric p H alteration) in nursing infants, caution is advised. Consider alternatives, especially while nursing a premature or jaundiced infant.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy may alter cimetidine pharmacokinetics (increased volume of distribution, unchanged clearance). No specific dose adjustment is recommended, but monitor for therapeutic effect and toxicity. In severe renal impairment (creatinine clearance <30 m L/min), reduce dose to 300 mg every 12 hours.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Cimetidine is a potent inhibitor of CYP450 enzymes, notably CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Monitor for drug interactions, especially with warfarin, theophylline, phenytoin, and lidocaine. Adjust doses of these drugs when co-administered. Cimetidine can cause confusion in elderly patients, particularly with high doses or renal impairment. Administer IV slowly over at least 20 minutes to avoid hypotension and cardiac arrhythmias. In renal impairment (Cr Cl <30 m L/min), reduce dose to 300 mg q12h. For acid suppression, IV route is reserved for when oral therapy is not feasible.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Do not stop taking this medication abruptly without consulting your doctor.,Report any signs of confusion, especially if you are elderly or have kidney problems.,Avoid smoking, as it can increase stomach acid and reduce drug effectiveness.,Notify your doctor if you are taking blood thinners (e.g., warfarin), asthma medications (e.g., theophylline), or seizure medications (e.g., phenytoin).,This medication may cause dizziness or drowsiness; avoid driving until you know how it affects you.,Do not take over-the-counter pain relievers like ibuprofen or aspirin unless approved by your doctor, as they can worsen stomach issues.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Axitinib, a tyrosine kinase inhibitor used in renal cell carcinoma, is primarily metabolized by CYP3A4 and also by CYP1A2 and CYP2C19. Cimetidine, a histamine H2 receptor antagonist, is a known inhibitor of multiple CYP450 enzymes including CYP1A2, CYP2C19, and CYP3A4. Co-administration of cimetidine may decrease the metabolism of axitinib, potentially leading to increased plasma concentrations of axitinib, thereby enhancing its therapeutic effects and increasing the risk of dose-dependent toxicities such as hypertension, proteinuria, and gastrointestinal perforation."
"Cimetidine, a potent inhibitor of CYP1A2 and other cytochrome P450 enzymes, can reduce the metabolism of zolmitriptan, which is partially metabolized by CYP1A2. This leads to increased serum concentrations of both drugs, potentially enhancing the risk of zolmitriptan-related adverse effects such as serotonin syndrome, hypertension, and cardiac events. Concurrent use may also elevate cimetidine levels, though the clinical significance is less clear."
"Cimetidine, a potent inhibitor of cytochrome P450 (CYP) enzymes, particularly CYP2D6 and CYP3A4, significantly decreases the metabolism of fesoterodine, a prodrug that is rapidly converted to its active metabolite 5-hydroxymethyl tolterodine (5-HMT). This metabolic inhibition can substantially elevate the serum concentrations of the active metabolite, increasing the risk of anticholinergic adverse effects such as dry mouth, constipation, blurred vision, urinary retention, and potential cognitive impairment. In patients with renal or hepatic impairment, the elevations may be even more pronounced, warranting caution."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing gastric acid secretion (basal and stimulated) by inhibiting c AMP production.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 300 mg intravenously every 6-8 hours or as continuous IV infusion at 37.5-50 mg/hour. Maximum 2400 mg/day.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Cimetidine crosses the placenta. First trimester: No increased risk of major malformations in human studies, but animal studies show fetal effects at high doses. Second and third t. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.